In one paragraphArticle in Journal of Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Kayenat ParveenDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
J Alexander RossDepartment of Geriatric Medicine and Center for Translational and Behavioral Neuroscience, University Duisburg-Essen, Essen, Germany.ORCID 0000-0001-9286-2748 Hendrik van der WurpDepartment of Geriatric Medicine and Center for Translational and Behavioral Neuroscience, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-1044-417X Monika Balzer-GeldsetzerDepartment of Neurology, Philipps University Marburg, Marburg, Germany.
Thomas GasserDepartment of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University Tübingen, and German Center for Neurodegenerative Diseases, Tübingen, Germany.ORCID 0000-0002-1069-1146 Rüdiger Hilker-RoggendorfDepartment of Neurology, J.W. Goethe University, Frankfurt/Main, Germany.
Elke KalbeMedical Psychology, Neuropsychology, Gender Studies & Centre for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-8603-2545 Inga Liepelt-ScarfoneDepartment of Parkinson, Sleep and Movement Disorders, Centre of Neurology, University Hospital Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Brit MollenhauerParacelsus-Elena Clinic, Centre of Parkinsonism and Movement Disorders, Kassel, Germany.
Sandra RöskeDepartment of Parkinson, Sleep and Movement Disorders, Centre of Neurology, University Hospital Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.ORCID 0000-0002-8262-4356 Annika SpottkeDepartment of Parkinson, Sleep and Movement Disorders, Centre of Neurology, University Hospital Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.ORCID 0000-0001-9854-2972 Claudia TrenkwalderParacelsus-Elena Clinic, Centre of Parkinsonism and Movement Disorders, Kassel, Germany.ORCID 0000-0001-6407-1199 Karsten WittDepartment of Neurology, School of Medicine and Health Sciences, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
Richard DodelDepartment of Geriatric Medicine and Center for Translational and Behavioral Neuroscience, University Duisburg-Essen, Essen, Germany.ORCID 0000-0003-2044-6299 Ullrich WüllnerDepartment of Parkinson, Sleep and Movement Disorders, Centre of Neurology, University Hospital Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.ORCID 0000-0002-3132-0790 Alfredo RamirezDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0003-4991-763X Maria Carolina DalmassoDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-4901-9955 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Parkinson's disease (PD) is marked by motor symptoms and often accompanied by mild cognitive impairment (PD-MCI), affecting up to 50% of patients and preceding PD dementia (PDD). Genetic factors may influence this progression, yet the underlying mechanisms remain unclear. This study investigated genetic factors influencing the progression from PD-MCI to PDD using polygenic risk scores (PRS). A genome-wide association study (GWAS) was conducted using data from the LANDSCAPE study. Multivariable Cox regression, Kaplan-Meier survival analysis, and concordance statistics assessed the relationship between PRS and PDD progression. No significant association was found between PD PRS and the risk of developing PDD.
Indexed as
Alzheimer DiseaseCognitive DysfunctionDementiaDisease ProgressionParkinson DiseaseAgedFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMiddle AgedMultifactorial InheritanceAlzheimer's diseasegenome-wide association studymild cognitive impairmentParkinson's diseasesingle nucleotide polymorphism
Identifiers
PMID40739885
PMCPMC13347514
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390